Why is the Medibank share price struggling to gain ground in May?

We check what's going on with shares in the private health insurer.

| More on:
retirement investing represented by older investor looking concerned at computer screen

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Medibank share price has moved in circles since the beginning of May
  • Weak market sentiment and volatility have dragged down the company's shares
  • Medibank reaffirmed its FY22 outlook at the Macquarie Australia Conference

The Medibank Private Ltd (ASX: MPL) share price has failed to make a move in the past three weeks.

Despite the company delivering a positive update at the Macquarie Australia Conference earlier this month, Medibank shares are travelling sideways.

For the recent period, Medibank shares are fetching just one cent more than they did at market close on 29 April.

Today, the private health insurance company's shares closed at $3.21, down 0.93% for the day.

What's happened to the Medibank share price in May?

Amid recent broader market weakness, the Medibank share price has been weighed down regardless of the company reaffirming its FY22 outlook.

Management noted in its latest presentation that private health insurance participation growth remains strong. This is due to more people continuing to prioritise their health and wellbeing, the company said.

Notably, Medibank Private has recorded six consecutive quarters of industry policyholder growth.

New-to-industry and younger groups are becoming major contributors to growth which are positive signs for industry sustainability.

Medibank stated it's on track to achieve 3.1% to 3.3% of policyholder growth in FY22.

Furthermore, the underlying average net claims expense per policy unit is forecast to be around 2.3% among resident policyholders.

The company advised it will deliver $15 million in productivity savings. In total, management expenses are predicted to come in at roughly $530 million for the full year.

Is this a buying opportunity?

One broker weighed in on the Medibank share price at the start of this month.

The team at Macquarie cut its 12-month price target by 1.5 % to $3.20 for Medibank shares.

It appears analysts have a similar view to investors' perceived value of the company's shares.

Looking further back, Citi has the most bullish outlook for the private health insurer's shares, upgrading them to a buy.

The broker also raised its rating by 4.3% to $3.65 per share following the company's half year results.

Based on today's price, this implies a potential upside of around 13.7%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »